ClinicalTrials.Veeva

Menu

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid

Merz Pharmaceuticals logo

Merz Pharmaceuticals

Status and phase

Completed
Phase 3

Conditions

Bilateral Blepharospasm (BEB)

Treatments

Drug: IncobotulinumtoxinA (Xeomin), 35 Units
Drug: Placebo
Drug: IncobulinumtoxinA (Xeomin), 25 Units
Drug: IncobotulinumtoxinA (Xeomin), 12.5 Units

Study type

Interventional

Funder types

Industry

Identifiers

NCT01896895
2012-004821-26 (EudraCT Number)
MRZ60201_3074_1

Details and patient eligibility

About

This phase 3 study will serve to collect efficacy and safety data of two different doses of NT 201 in subjects suffering from Bilateral Blepharospasm (BEB) who are BTX treatment-naïve.

In this study, BTX treatment-naïve subjects are defined as those who have not received BTX treatment within the last 12 months for the treatment of BEB. This definition aims to avoid bias by comparison of treatment effects in the subject's assessments. Furthermore, this study will substantiate the existing efficacy and safety database for the indication BEB.

Full description

Subjects to receive one injection with NT 201 or placebo at baseline of the placebo-controlled first cycle. Thereafter, all subjects entering the Open-Label Extension Period (OLEX) to receive a second injection of NT 201 (second injection cycle).

Enrollment

61 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female out-patients age ≥ 18 and ≤ 80 years.
  • A clinical diagnosis of bilateral BEB characterized by spontaneous, spasmodic, intermittent or persistent involuntary contractions of orbicular oculi muscles.
  • A need for injection of BTX defined as a Jankovic Rating Scale [JRS] severity subscore ≥ 2.
  • Treatment-naïve subject defined as at least 12 months without BTX of any serotype for the treatment of BEB before administration of IP.

Exclusion criteria

  • Subject with any previous unsuccessful treatment with BTX of any serotype for the treatment of BEB.
  • Atypical variant of BEB (e.g., apraxia of the eyelid opening) caused by inhibition of levator palpebrae muscle.
  • Neuroleptic-induced blepharospasm.
  • Myotomy or denervation surgery in the affected muscles (e.g., peripheral denervation, spinal cord stimulation) and surgery in the upper face.
  • Generalized disorders of muscles activity (e.g., myasthenia gravis in particular ocularis, Lambert-Eaton-Syndrome, amyotrophic lateral sclerosis) or any other significant neuromuscular dysfunction which might interfere with the study.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

61 participants in 3 patient groups, including a placebo group

IncobotulinumtoxinA (Xeomin) 25U per eye
Experimental group
Description:
Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
Treatment:
Drug: IncobulinumtoxinA (Xeomin), 25 Units
Drug: IncobotulinumtoxinA (Xeomin), 35 Units
IncobotulinumtoxinA (Xeomin) 12.5U per eye
Experimental group
Description:
Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
Treatment:
Drug: IncobotulinumtoxinA (Xeomin), 12.5 Units
Drug: IncobotulinumtoxinA (Xeomin), 35 Units
Placebo
Placebo Comparator group
Description:
Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session. Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
Treatment:
Drug: Placebo
Drug: IncobotulinumtoxinA (Xeomin), 35 Units

Trial contacts and locations

11

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems